Sleepiness and the Risk of Falling

This study has been completed.
Sponsor:
Collaborator:
Information provided by:
National Institute on Aging (NIA)
ClinicalTrials.gov Identifier:
NCT00383357
First received: September 28, 2006
Last updated: September 19, 2007
Last verified: September 2007
  Purpose

The purpose of this project is to examine the impact of sleeping pills and waking up in the middle of the night on walking balance and cognitive function, to identify risk factors for falls in older adults. A significant percentage of falls, approximately 33 to 52 percent, occur during the nighttime and morning hours when people are normally sleeping; therefore, it is possible that sleep and sleeping medication related impairments in balance may contribute to this risk.


Condition Intervention
Aging
Balance
Sleep
Drug: zolpidem

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety Study
Intervention Model: Crossover Assignment
Masking: Double-Blind
Primary Purpose: Treatment
Official Title: Aging, Hypnotics, Sleep Inertia and the Risk of Falling

Resource links provided by NLM:


Further study details as provided by National Institute on Aging (NIA):

Primary Outcome Measures:
  • Changes in gait stability: normal walking and beam walking across force plates (platforms with sensors that measure the force (energy) that occurs when the foot contacts the ground during walking)
  • at 1, 15, and 30 minutes after awakening in the middle of the night during all three visits

Secondary Outcome Measures:
  • Changes in gait stability: normal walking and beam walking across force plates at 1, 15, and 30 minutes after awakening in the morning during all three visits.
  • cognitive performance: computerized assessment of executive function at 5, 20, and 35 minutes after awakening in the middle of the night and in the morning during all three visits.
  • sleep architecture: visual scoring of the sleep EEG across 8 hours of scheduled sleep during all three visits.

Estimated Enrollment: 24
Study Start Date: August 2004
Detailed Description:

Awakening from sleep is well documented to impair cognitive performance in young adults. This phenomenon, called sleep inertia, has been reported to impair performance just as much as one night of total sleep deprivation, suggesting that there are significant functional consequences to sleep inertia. However, whether walking stability is impaired by sleep inertia is unknown. If sleep inertia impairs walking stability, it could be an important but currently unrecognized risk factor for falls in older adults. Also, the impact of aging on sleep inertia-related impairments in cognitive performance is unknown.

Sleeping medication use is higher in older than younger adults, and is a risk factor for falls. Current evidence suggests that sleeping medications impair walking stability and cognitive performance in young and older adults during wakefulness; however, no study has examined walking stability and cognitive performance of young and older adults upon awakening from sleep at night after taking a hypnotic (sleeping medication). Therefore, the purpose of this study is to determine whether sleep inertia and hypnotic use impairs walking stability and cognitive performance more in healthy older than in healthy younger adults. It is expected that findings from the proposed study will provide evidence for sleep inertia as a risk factor for falls in older adults.

Twelve older (aged 60-85) and twelve younger (aged 18-35) healthy male and female volunteers will participate in the study. The investigational procedures will include medical screening (e.g., physical, blood and urine tests, and bone mineral density assessment), home monitoring of sleep schedules for three weeks, and three overnight visits in the laboratory spaced approximately one week apart. During the laboratory visits, participants will be awakened in the middle of the night to perform walking stability and cognitive function tests. Before going to bed, participants will take either a placebo pill or a sleeping medication. On one of the visits, participants will be asked to go to bed about 2 hours later than usual.

  Eligibility

Ages Eligible for Study:   18 Years to 85 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Males and females
  • Aged 18 to 35, or 60 to 85
  • Lived at Denver altitude or higher for at least one year
  • Stable treated diseases: thyroid dysfunction (including hypothyroidism and hyperthyroidism), hypertension, hypercholesterolemia, urinary incontinence, prostate enlargement, gastroesophageal reflux disease, irritable bowel syndrome

Exclusion Criteria:

  • Aged 36 to 59, under 18, or over 85
  • BMI less than 18.6 or greater than 30 kg/m2, women below 95 pounds regardless of BMI
  • Sleep duration is less than 5 or more than 9 hours
  • Sensitivity to sleeping medications
  • Night work in the preceding 6 months
  • Transmeridian travel (across more than 2 time zones) in the last 1 month
  • Bone mineral density DXA T-score of less than -1.75
  • Orthostatic intolerance
  • Prior history of falls in past year
  • Prior history of injurious fall in past 5 years
  • Hip fracture following a fall
  • Difficulty rising from a sitting position without use of hands to push off
  • Needing to walk slowly or with a wide base of support to maintain balance
  • Hormone replacement therapy for less than 3 months
  • Connective Tissue and Joint Disorders
  • Neurologic Disorders
  • Musculoskeletal Disorders
  • Immune Disorders
  • Sleep Disorders
  • Chronobiologic Disorders
  • Cardiovascular Disorders
  • Respiratory Disorders
  • Kidney and Urinary Tract Disorders
  • Infectious Diseases
  • Gastrointestinal Disorders
  • Hematopoietic Disorders
  • Neoplastic Diseases
  • Endocrine and Metabolic Diseases
  • Psychopathology
  • Dementia
  • Drug dependency
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00383357

Locations
United States, Colorado
University of Colorado at Boulder
Boulder, Colorado, United States, 80309
Sponsors and Collaborators
Investigators
Principal Investigator: Kenneth P. Wright, PhD Department of Integrative Physiology, University of Colorado
Study Director: Danielle J. Frey, PT, MS Department of Integrative Physiology, University of Colorado
  More Information

Publications:
Additional publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
ClinicalTrials.gov Identifier: NCT00383357     History of Changes
Other Study ID Numbers: AG0070, 5R03AG024621-02, 5M01RR000051-45
Study First Received: September 28, 2006
Last Updated: September 19, 2007
Health Authority: United States: Federal Government

Keywords provided by National Institute on Aging (NIA):
Performance
Gait stability
sedative
hypnotic
quality of life
sleep disorder
wakefulness
sleeping pills
Cognitive function

Additional relevant MeSH terms:
Hypnotics and Sedatives
Zolpidem
Central Nervous System Depressants
Physiological Effects of Drugs
Pharmacologic Actions
Central Nervous System Agents
Therapeutic Uses
GABA-A Receptor Agonists
GABA Agonists
GABA Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action

ClinicalTrials.gov processed this record on July 20, 2014